Thomas DiVincent

Thomas A. DiVincent is Managing Director Life Sciences at True North Capital Partners LLC. In this role Tom focuses on introducing a full range of advisory services to clients in the Life Sciences space comprising ethical pharmaceuticals, biotechnology, medical devices, consumer pharmaceuticals (OTC), nutraceuticals and related areas. Advisory services includes origination, structuring, negotiation, valuation, due diligence and execution of buy and sell-side M&A, joint ventures and other collaborative business arrangement.

Tom is an accomplished and seasoned executive with over 40 years of experience in consulting, investment banking and corporate development roles. His career documents a successful track record originating, structuring, negotiating and executing transactions which achieve strategic, operational and financial objectives. Deal experience includes acquisitions and divestitures of legal entities and/or assets including PP&E, products, technologies and related intellectual property. Also, structuring and negotiating joint ventures, partnerships and other collaborative business arrangements. Special strength in “cross border” transactions for clients seeking to expand an existing presence or enter new markets internationally.

Prior to joining TrueNorth Tom was a Principal at High Mountain Advisors LLC (HMA). Prior to HMA Tom served as Executive Director Corporate Development and, subsequently, as Head of Worldwide Human Health Business Development for Merck & Co. Inc. Before joining Merck, Tom held several positions of increasing responsibility to include: Vice President/Division Head of Bankers Trust with responsibility for buy and sell-side M&A, recapitalizations and acquisition finance; Director of Corporate Development for American Cyanamid Company, a conglomerate operating in chemicals, medical devices, generic pharmaceuticals and branded consumer products; and as Manager-Acquisition Consulting Services at Price Waterhouse (now PwC).

Tom earned a Bachelor of Science in Economics from St. Peter’s University and am MBA from the NYU Stern School of Business. He is a Member of the Association of Corporate Growth.